Skip Ribbon Commands
Skip to main content
Sign In
{{'GLOBAL_MESSAGE_HEADLINE' | translate}}
{{'GLOBAL_MESSAGE_CHOOSE_LANG' | translate}}
en
日本語
中文
{{'GLOBAL_MESSAGE_OR' | translate}}
{{'GLOBAL_MESSAGE_SET_COUNTRY' | translate}}
{{'ELOQUA_BANNER_DECLINE_CONFIRM' | translate}}
{{'ELOQUA_BANNER_DECLINE_CONFIRM_CLOSE' | translate}}
{{'ELOQUA_BANNER_ACCEPT' | translate}}
{{'ELOQUA_BANNER_DECLINE' | translate}}
COVID-19 Response & Business Continuity
Employee Health & Safety Latest News Business Continuity and Customer Letters External Research Program Resources



Our COVID-19 Response

Terumo BCT and Terumo Corporation, our parent company, are actively responding to the current outbreak of coronavirus disease (COVID-19).
This includes focusing on the health and safety of our employees, maintaining a strong product supply, growing our external research program, and leveraging our resources and technologies in the fight against COVID-19.
In all cases, our response is guided by our mission: Contributing to Society Through Healthcare.





Employee Health & Safety

Our utmost priority is the continued health and well-being of our 7,100 employees worldwide.


Latest News



Webinar On-Demand: Exchanging Experience and Knowledge During the COVID-19 Pandemic  

This International Society of Blood Transfusion (ISBT) corporate partner education webinar features Michael Schmidt, Raymond Goodrich & Marcia Cardoso.



Terumo BCT’s Mirasol reduces the virus causing COVID-19 below the limit of detection in plasma and platelets  

Vox Sanguinis, a peer-reviewed medical journal, published results from a Terumo BCT study conducted in collaboration with top researchers at Colorado State University. The study examined how well the Mirasol system treated platelets and plasma against the virus causing COVID-19.

Terumo Donates USD 2.4 Million in Cash and Products to Support COVID-19 Pandemic Relief Efforts Worldwide  

Terumo Corporation is donating USD 2.4 million in cash and products to support the novel coronavirus disease relief efforts worldwide – including a USD 1 million donation to the COVID-19 Solidarity Response Fund for WHO.



Terumo BCT and Marker Therapeutics received the first device FDA Emergency Use Authorization (EUA) to treat acute respiratory failure in COVID-19 patients  

“We thank the Food and Drug Administration for their expedited review, which provides another treatment option for patients in the ICU to help reduce the severity of the disease,” says Antoinette Gawin, CEO and President of Terumo BCT, and David Cohen, Chairman of Marker.




Business Continuity & Customer Letters


We are exercising maximum effort to maintain a stable supply of products to meet healthcare needs.


Customer Letter: Update on Terumo BCT Global Supply Chain and Logistics in Response to the Novel Coronavirus (SARS-CoV-2) Pandemic  

Terumo BCT has a comprehensive and established Business Continuity Policy in place, designed to safeguard our associates around the world and our ability to deliver products worldwide.



Terumo BCT has strong business continuity plans to help ensure continued availability of our products that are used to treat critically ill patients and that collect and process blood and blood products. We know a safe, sustainable and readily available supply of blood is vital to those with serious conditions and diseases.


View business continuity infographic

Download Business Continuity Infographic

External Research Program for Investigator-Initiated Studies

Discovery never stops. We share a passion for thinking in new and different ways and support COVID-19 studies around the globe with scientific and medical merit developed by independent investigators or academic sponsors around the globe. Visit our External Research Program (ERP) for more information.


​​​​​

{{'SEARCH_MODAL_TITLE' | translate }}
{{'SEARCH_MODAL_OR' | translate }}

{{'SEARCH_MODAL_BROWSE' | translate }}
{{'SEARCH_MODAL_CHOOSE_LANGUAGE' | translate }} {{'SEARCH_MODAL_CHANGE_LANGUAGE' | translate }}
{{$index+1}}. {{s.label}}